BioLeap, Inc Revenue
Pharmaceutical Manufacturing • 
United States • 1-10 Employees
BioLeap, Inc revenue & valuation
| Annual revenue | $171,110 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $547,552 |
| Total funding | No funding |
Key Contact at BioLeap, Inc
Clive Hammant
Vice President Licensing
Company overview
| Headquarters | United States |
| Phone number | +18138846300 |
| Website | |
| NAICS | 3254 |
| Employees | 1-10 |
| Socials |
About BioLeap, Inc
BioLeap is a drug design company that leverages its proprietary technology platform to identify and optimize lead compounds where other approaches have not been successful. Unlike random screening approaches, BioLeap’s hypothesis-driven method is particularly effective for designing and improving lead compounds for “difficult” targets where traditional methods have failed. BioLeap’s methodology conceptualizes molecules of practically infinite structural diversity and accurately predicts their relative binding affinity to a target protein. As a result, dramatically fewer compounds need to be synthesized and tested experimentally before achieving pre-clinical milestones. BioLeap creates novel compounds with intellectual property protection, enhances the intellectual property estate around existing compounds, avoids obstructive patents, and generates fast-follower compounds for early market entry.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
BioLeap, Inc has never raised funding before.
United Kingdom
South Africa
Frequently asked questions
4.8
40,000 users
